The EMA is suffering heavier than expected job losses as a result of its relocation to the Netherlands, forcing it to scale back and suspend more of its activities. International collaborations, development of guidelines and other tasks will slow significantly as the EMA focuses its dwindling resources on key functions.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,